David Taylor

David Taylor is a Professor Chair in Psychopharmacology at the Institute of Pharmaceutical Science. His research focuses on mental health, clinical trials, and pharmacoeconomics, with a particular emphasis on drug use in mental health contexts. He has contributed to over 377 publications and 11 research projects, including initiatives aimed at improving drug safety monitoring and developing digital tools for safer prescribing. His work addresses critical issues such as clozapine-related side effects, mortality analysis, and personalized medicine strategies.

• Key Projects:
  • Psychiatric pharmacist intervention to improve treatment adherence using CBT models (2015-2018).
  • Development of the Medichec app for vulnerable adults (2023).
  • Signal detection methods for adverse drug reactions in electronic health records (2015-2018).

Research interests include clozapine pharmacology, antipsychotic drug efficacy, and the application of digital tools in healthcare. His recent work highlights advancements in understanding brain connectivity modulation by oxytocin and the safety profile of clozapine.

Awards and grants include funding from the University of London, Medical Research Council, and GSK, among others.